New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study

Area of Science:

• Medicinal Chemistry
• Computational Drug Discovery
• Pharmacology

Background:

• Dipeptidyl peptidase IV (DPP IV) is a key target for antidiabetic drug development.
• DPP IV inhibitors enhance glycemic control by preserving incretin hormones like GLP-1 and GIP.

Purpose of the Study:

• To identify novel dipeptidyl peptidase IV (DPP IV) inhibitors using virtual screening.
• To discover potential lead compounds for new antidiabetic therapies.

Main Methods:

• Employed a hierarchical virtual screening cascade with 2D and 3D filters.
• Generated structure-based pharmacophore models from co-crystallized DPP IV ligands.
• Validated pharmacophore models and screened NCI and in-house drug databases.
• Utilized Lipinski's rule of 5, rotatable bond counts, physicochemical filters, and high-throughput molecular docking.

Main Results:

• Discovered five novel compounds with potential DPP IV inhibitory activity.
• Validated the identified compounds through in vitro bioassays.
• Successfully identified potential lead compounds for antidiabetic drug development.

Conclusions:

• Virtual screening is an effective strategy for identifying novel DPP IV inhibitors.
• The identified compounds represent promising candidates for further development as antidiabetic agents.